Glucagon-like peptide-1 (GLP-1) receptor agonists or incretin mimetics are a class of drugs that work by copying the mechanism of incretin. It is a hormone that lowers blood sugar levels by stimulating the secretion of insulin, inhibiting glucagon production and delaying emptying of the stomach.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor analogue that is used to manage Type 2 Diabetes and body weight. In a condition called non-alcoholic steatohepatitis (NASH), this drug reduces fat build-up in the liver. The weight loss observed with semaglutide is predominantly from the reduction of fat tissue. The mechanism of body weight loss involves lowering of appetite both in the fasting and postprandial state, leading to a low daily calorie intake.
Semaglutide is available in both injectable and oral medication forms. Semaglutide once-weekly subcutaneous injection is approved worldwide for the management of Type 2 Diabetes. Research studies have shown that semaglutide may provide the benefits of GLP-1 receptor agonist in tablet form also. The starting dose of oral semaglutide is 3 mg once daily. The proposed treatment doses of oral semaglutide are 7 and 14 mg. Adults with Type 2 Diabetes can be